Jurjen F Krommenhoek, Jasper A F Demandt, Nienke van Rein, Frederikus A Klok, Menno V Huisman, Paul L den Exter
{"title":"A safety profile on idarucizumab for dabigatran reversal: an update.","authors":"Jurjen F Krommenhoek, Jasper A F Demandt, Nienke van Rein, Frederikus A Klok, Menno V Huisman, Paul L den Exter","doi":"10.1080/14740338.2026.2760111","DOIUrl":"10.1080/14740338.2026.2760111","url":null,"abstract":"<p><strong>Introduction: </strong>Idarucizumab has been widely adopted since its approval as the only reversal agent for dabigatran. Since then, evidence on its effectiveness, safety, and real-world use has continued to accumulate.</p><p><strong>Areas covered: </strong>This review summarizes the pharmacological characteristics of idarucizumab, the clinical evidence supporting its use, and practical considerations for administration, including post-reversal care. We also provide expert opinion on its role as reversal agent. Key literature on clinical evidence, pharmacology, and safety was identified through PubMed searches and screening of reference lists.</p><p><strong>Expert opinion: </strong>Idarucizumab remains the only approved targeted antidote for dabigatran and is likely to retain this position in the near term. However, evidence for clinical benefit remains limited to observational data and a single-arm trial conducted without a comparator. High cost and lower dabigatran use compared with other DOACs may make routine stocking of idarucizumab impractical in rural or resource-limited settings. In our expert opinion, its indication can be complex, particularly because trial-based bleeding definitions may not align with clinical practice; therefore, multidisciplinary input may be required to support appropriate use. Furthermore, we advocate that multidisciplinary care should extend beyond achieving hemostasis. Dedicated aftercare and anticoagulation stewardship could optimize clinical outcomes.</p>","PeriodicalId":12232,"journal":{"name":"Expert Opinion on Drug Safety","volume":" ","pages":"1-8"},"PeriodicalIF":3.0,"publicationDate":"2026-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149341438","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Emilio Russo, Antonio Leo, Roberta Roberti, Maria Pisano, Brunella Piro, Adele Emanuela De Francesco, Luca Gallelli, Maria Cristina Caroleo
{"title":"A learning pharmacovigilance system for frail patients: integrating real-world data, artificial intelligence, clinical pharmacology and medicines optimization to prevent medication-related harm.","authors":"Emilio Russo, Antonio Leo, Roberta Roberti, Maria Pisano, Brunella Piro, Adele Emanuela De Francesco, Luca Gallelli, Maria Cristina Caroleo","doi":"10.1080/14740338.2026.2763268","DOIUrl":"https://doi.org/10.1080/14740338.2026.2763268","url":null,"abstract":"<p><strong>Introduction: </strong>Frail patients face changing medication-related risks that require repeated clinical reassessment. We propose a learning pharmacovigilance framework that connects safety evidence with medication decisions and outcomes.</p><p><strong>Areas covered: </strong>We searched PubMed/MEDLINE and Scopus on 8 September 2026 for publications from 2015-2026; we searched ClinicalTrials.gov on the same date. We purposively selected articles for this narrative review. Six layers connect pharmacological knowledge, longitudinal data, artificial intelligence, clinical translation, outcome capture, and governed learning. We distinguish prognosis, clinical causal attribution, and treatment-effect estimation, and examine frailty assessment, prescribing-optimization trials, large language models, and regulatory requirements for updates. Clinical translation assigns responsibility for medication review, decisions, and follow-up. Outcome assessment includes withdrawal events, while implementation requires workload assessment and silent prospective testing.</p><p><strong>Expert opinion: </strong>Four randomized trials of prescribing optimization did not demonstrate significant benefit on their primary clinical outcomes; the integrated framework remains clinically unvalidated. Comparative evaluation should separate the contribution of structured clinical review from that of outcome-linked updating; over the next five years, we expect local model control and version traceability to become priorities for regulated medication-safety applications.</p>","PeriodicalId":12232,"journal":{"name":"Expert Opinion on Drug Safety","volume":" ","pages":""},"PeriodicalIF":3.0,"publicationDate":"2026-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149393319","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Artificial intelligence-driven pharmacovigilance: transforming signal detection, real-world drug safety monitoring, and regulatory decision-making.","authors":"Sachin Kumar, Saurabh Chaturvedi","doi":"10.1080/14740338.2026.2759573","DOIUrl":"10.1080/14740338.2026.2759573","url":null,"abstract":"<p><strong>Introduction: </strong>Pharmacovigilance is undergoing rapid transformation due to the expansion of digital healthcare systems, biomedical data generation, and pharmaceutical innovation. Conventional drug-safety monitoring methods remain limited by underreporting, delayed signal identification, fragmented datasets, and restricted predictive capability. Artificial intelligence (AI) has emerged as a promising approach for improving signal detection, real-world drug-safety surveillance, and regulatory decision-making.</p><p><strong>Areas covered: </strong>This review evaluates application of AI technologies in modern pharmacovigilance and regulatory science. It discusses use of machine learning, deep learning, neural networks, and natural language processing for adverse-event detection, literature mining, signal prioritization, and analysis of electronic health records (EHR) and social-media data. Emerging technologies, including large language models, federated learning, blockchain, digital twins, and Internet of Things (IoT)-enabled monitoring systems, are also explored. Literature was identified through structured searches of MEDLINE/PubMed, Scopus, Web of Science, Embase, and Google Scholar, covering publications from January 2000 to February 2026.</p><p><strong>Expert opinion: </strong>AI-driven pharmacovigilance has potential to improve real-time safety surveillance, predictive risk assessment, and automated regulatory workflows. However, broader implementation remains challenged by concerns related to interpretability, data quality, cybersecurity, algorithmic bias, and regulatory validation. Future progress will depend on transparent, explainable, and human-supervised AI systems integrated within globally interoperable healthcare infrastructures.</p>","PeriodicalId":12232,"journal":{"name":"Expert Opinion on Drug Safety","volume":" ","pages":"1-21"},"PeriodicalIF":3.0,"publicationDate":"2026-11-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149319532","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Momelotinib for the treatment of myelofibrosis in patients with moderate-to-severe anemia: a drug safety evaluation.","authors":"Andrea Duminuco, Patrick Harrington","doi":"10.1080/14740338.2026.2756129","DOIUrl":"https://doi.org/10.1080/14740338.2026.2756129","url":null,"abstract":"<p><strong>Introduction: </strong>Momelotinib is an oral inhibitor of Janus kinase 1 and 2 (JAK1/JAK2) and of activin A receptor type 1 (ACVR1). Its key distinguishing feature is the suppression of hepcidin through ACVR1 inhibition, which mitigates the iron-restricted anemia observed in myelofibrosis (MF) due to the hyperinflammatory state. It is the first agent approved for intermediate- or high-risk MF with potential to treat anemia and reduce transfusion dependence.</p><p><strong>Areas covered: </strong>We review the pharmacology, efficacy, and principally, the safety profile of momelotinib in MF patients with moderate-to-severe anemia. We integrate the controlled safety data of SIMPLIFY-1, SIMPLIFY-2 and MOMENTUM with the rapidly expanding post-marketing real-world evidence (>700 patients across five independent cohorts) and place the profile in the context of the alternative second-line JAK inhibitors fedratinib and pacritinib.</p><p><strong>Expert opinion: </strong>Momelotinib reshapes the therapeutic algorithm for the anemic myelofibrosis patient, an unmet need that other JAK inhibitors aggravate rather than relieve. The trial-derived haematological profile is favorable, but real-world monitoring has surfaced two signals - treatment-emergent nephropathy and peripheral neuropathy - that were not fully detected in the registration program and now warrant active monitoring. Outstanding questions concern long-term renal and neurological safety, optimal sequencing, and survival benefit.</p>","PeriodicalId":12232,"journal":{"name":"Expert Opinion on Drug Safety","volume":" ","pages":"1-6"},"PeriodicalIF":3.0,"publicationDate":"2026-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149319534","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Michael Colwill, Sailish Honap, Fernando Magro, Silvio Danese, Laurent Peyrin-Biroulet
{"title":"Long-term safety of Etrasimod in ulcerative colitis: a comprehensive review.","authors":"Michael Colwill, Sailish Honap, Fernando Magro, Silvio Danese, Laurent Peyrin-Biroulet","doi":"10.1080/14740338.2026.2759574","DOIUrl":"https://doi.org/10.1080/14740338.2026.2759574","url":null,"abstract":"<p><strong>Introduction: </strong>Etrasimod is an oral sphingosine-1-phosphate receptor modulator approved for the treatment of moderate to severe ulcerative colitis. Its targeted mechanism, once-daily dosing and oral formulation make it an important addition to the therapeutic landscape. However, its safety profile and optimal clinical positioning require careful evaluation.</p><p><strong>Areas covered: </strong>This narrative review examines the pharmacology, efficacy and safety of etrasimod in ulcerative colitis, drawing on evidence from the OASIS, ELEVATE UC and ENLIGHT UC trial programmes, open-label extension studies, meta-analyses, pharmacovigilance reports and emerging real-world cohorts. The practicalities of prescribing and monitoring are also covered. A literature search was conducted in MEDLINE to identify appropriate studies.</p><p><strong>Expert opinion: </strong>Current evidence supports etrasimod as a generally well-tolerated treatment option, with low rates of serious adverse events, serious infections, opportunistic infections and malignancy which do not differ substantially from placebo. Key safety considerations include first-dose bradycardia, atrioventricular conduction abnormalities, macular oedema, hepatic enzyme elevations, and lymphopenia, all of which necessitate appropriate screening and monitoring. Etrasimod may be particularly useful in patients with moderately active disease and limited prior advanced therapy exposure, whilst its reassuring safety profile and low risk of serious infection make it an attractive candidate for use in advanced combination therapy.</p>","PeriodicalId":12232,"journal":{"name":"Expert Opinion on Drug Safety","volume":" ","pages":""},"PeriodicalIF":3.0,"publicationDate":"2026-11-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149319533","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Meina Lv, Jianhui Chen, Bin Zheng, Bijuan Lin, Maobai Liu
{"title":"Exploration of cardiac adverse events associated with relugolix and degarelix: a multi-center pharmacovigilance study based on the FAERS database.","authors":"Meina Lv, Jianhui Chen, Bin Zheng, Bijuan Lin, Maobai Liu","doi":"10.1080/14740338.2025.2488239","DOIUrl":"10.1080/14740338.2025.2488239","url":null,"abstract":"<p><strong>Background: </strong>Relugolix and degarelix are gonadotropin-releasing hormone antagonist. However, the cardiac safety of relugolix and degarelix in the real world remains uncertain. The purpose of this study was to explore the potential association of relugolix and degarelix with cardiac adverse events (AEs).</p><p><strong>Methods: </strong>We queried the FAERS database and selected AE reports with relugolix or degarelix as the first suspected drug for analysis. Reporting odds ratio (ROR) and empirical Bayes geometric mean (EBGM) were used to quantify the association between relugolix and degarelix and cardiac AEs.</p><p><strong>Results: </strong>A total of 5,598 and 372 AEs were reported for relugolix and degarelix, respectively, with 235 and 56 being cardiac AEs. The cardiac AEs associated with relugolix and degarelix predominantly occurred in elderly patients (>65 years). Disproportionality analysis showed that relugolix was significantly associated with electrocardiogram/heart rate abnormality and palpitations, with the strongest signal for electrocardiogram abnormality (ROR = 77.54, EBGM = 68.64). While degarelix was significantly associated with cardiac failure, myocardial Infarction, and arrhythmia, with cardiac failure showing the strongest signal (ROR = 8.62, EBGM = 97.71).</p><p><strong>Conclusions: </strong>There are differences in the types of cardiac adverse events induced by relugolix and degarelix. Clinicians should consider their differences and enhanced electrocardiogram monitoring when prescribing GnRH antagonists to their patients.</p>","PeriodicalId":12232,"journal":{"name":"Expert Opinion on Drug Safety","volume":" ","pages":"2087-2094"},"PeriodicalIF":3.0,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143771758","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Pharmacovigilance insights into antibody-drug conjugates: a multi-database analysis of adverse events in leukemia treatment.","authors":"Honglong Wu, Xuchen Fan, Sheng Wu, Yiming Sun, Meiling Yu, Zhe Liu","doi":"10.1080/14740338.2025.2521365","DOIUrl":"10.1080/14740338.2025.2521365","url":null,"abstract":"<p><strong>Background: </strong>Gemtuzumab ozogamicin and inotuzumab ozogamicin play a crucial role in leukemia treatment. This study aims to explore multiple databases to identify adverse event (AE) signals that could enhance the safe use of these drugs.</p><p><strong>Methods design and methods: </strong>The FDA Adverse Event Reporting System (FAERS) database ASCII packages, covering 83 quarters from Q1 2004 to Q3 2024, were imported into SAS software (version 9.4) for data cleaning and analysis. Signal detection methods included the ROR, PRR, BCPNN and MGPS. The Japanese Adverse Drug Event Report database (JADER) and WHO Adverse Drug Event Report database (VigiAccess) were used to validate the results.</p><p><strong>Results: </strong>In FAERS and VigiAccess, the most frequent positive PT signal for gemtuzumab ozogamicin was 'febrile neutropenia.' In FAERS, the most frequent positive PT signal for inotuzumab ozogamicin was 'death.' The top five PTs with the highest signal intensity for both drugs across the three databases consistently included 'fibrin degradation products increased' and 'veno-occlusive liver disease.'</p><p><strong>Conclusion: </strong>Mining multiple databases enabled the identification of SOCs and AEs strongly associated with frequent adverse reactions to gemtuzumab ozogamicin and inotuzumab ozogamicin, offering valuable insights for clinical dosing guidance.</p>","PeriodicalId":12232,"journal":{"name":"Expert Opinion on Drug Safety","volume":" ","pages":"2175-2182"},"PeriodicalIF":3.0,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144301475","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Adverse events associated with obeticholic acid: a real-world, pharmacovigilance study.","authors":"Chunxia Zhang, Jianguo Wang","doi":"10.1080/14740338.2025.2487144","DOIUrl":"10.1080/14740338.2025.2487144","url":null,"abstract":"<p><strong>Background: </strong>Primary biliary cholangitis (PBC) is a chronic autoimmune liver disease predominantly affecting middle-aged women. While ursodeoxycholic acid (UDCA) is the first-line treatment, 30-40% of patients do not respond adequately, necessitating alternative therapies like Obeticholic Acid (OCA), an FXR agonist. The long-term safety of OCA remains insufficiently studied.</p><p><strong>Research design and methods: </strong>This study utilized the US FDA Adverse Event Reporting System (FAERS) to evaluate OCA safety through large-scale data mining, using disproportionality analyses (ROR, PRR, BCPNN, and MGPS) to identify adverse event signals.</p><p><strong>Results: </strong>From Q2 2016 to Q1 2024, 5,864 reports linked to OCA usage were identified among 13,245,871 AE reports. Significant signals across 27 System Organ Classes were found, with pruritus (12.54%), fatigue (4.16%), and nausea (1.64%) being the most prevalent adverse events. Severe hepatic events like liver failure were rare (0.6%). Median time to onset of AEs was 178 days. The most common outcomes reported were important medical events (18.6%), hospitalization (17.8%), and death (6.5%).</p><p><strong>Conclusion: </strong>This study provides key insights into the safety profile of OCA, highlighting the importance of monitoring for pruritus and hepatic complications, particularly within the first six months of treatment.</p>","PeriodicalId":12232,"journal":{"name":"Expert Opinion on Drug Safety","volume":" ","pages":"2077-2085"},"PeriodicalIF":3.0,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143751681","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Angioedema risk of thrombolytics: an integrated assessment using disproportionality analysis of the USFDA adverse event reporting system, case reviews and meta-analysis.","authors":"Kannan Sridharan","doi":"10.1080/14740338.2025.2574667","DOIUrl":"10.1080/14740338.2025.2574667","url":null,"abstract":"<p><strong>Background: </strong>Thrombolytic therapy is linked to angioedema, a serious adverse event, with higher risk when co-administered with renin-angiotensin-aldosterone system inhibitors (RAAS-i), particularly ACE inhibitors. However, this interaction remains incompletely characterized.</p><p><strong>Research design and methods: </strong>A multi-modal analysis: (1) USFDA Adverse Event Reporting System (AERS) disproportionality analysis including reporting odds ratio (ROR); (2) case report review; and (3) meta-analysis and trial sequential analysis of observational studies was performed. Drug interactions were evaluated using multiplicative models. Primary outcomes were mortality and life-threatening events.</p><p><strong>Results: </strong>Among 521 USFDA AERS reports, disproportionality signals were noted for alteplase (ROR: 3.1) and tenecteplase (ROR 2.85); and signal strength increased with RAAS-i co-administration. Mortality rates were comparable between thrombolytic monotherapy and thrombolytic - RAAS-i combination. Meta-analysis (24 studies; <i>n</i> = 3,007) confirmed increased risk with RAAS-i (OR: 3.12; 95% CI: 2.01-4.85). Case review (<i>n</i> = 60) showed mainly orofacial presentation (<i>n</i> = 59) within 3 hours, with 42 receiving RAAS-i and 16 requiring advanced airway management.</p><p><strong>Conclusion: </strong>This analysis suggests a consistent association increased angioedema risk with thrombolytic-RAAS-i combination therapy. Findings underscore the importance of careful risk assessment and monitoring in patients receiving RAAS-i therapy, especially those on ACEIs.</p>","PeriodicalId":12232,"journal":{"name":"Expert Opinion on Drug Safety","volume":" ","pages":"2135-2152"},"PeriodicalIF":3.0,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145274318","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"GLP-1-derived therapies and risk of sarcopenia: myth or reality?","authors":"André J Scheen","doi":"10.1080/14740338.2026.2640980","DOIUrl":"10.1080/14740338.2026.2640980","url":null,"abstract":"<p><strong>Introduction: </strong>Glucagon-like peptide-1 (GLP-1)-based therapies elicit a clinically significant reduction in body weight, an effect that correlates with improved clinical outcomes in individuals with type 2 diabetes and/or obesity. However, a risk of excessive reduction in skeletal muscle mass (SMM), potentially leading to sarcopenia, could minimize the benefit/risk balance of this pharmacological class.</p><p><strong>Areas covered: </strong>Human studies that investigated the effects of GLP-1-based therapies on changes in SMM, muscle strength/function and muscle structure/quality.</p><p><strong>Expert opinion: </strong>Mixed results were reported, some studies emphasizing an excessive SMM loss while others not but arguing for a protective effect against sarcopenia through improved muscle quality (less myosteatosis). This controversy may stem from the misinterpretation of changes in body composition, as well as from the scarcity of studies that rigorously assess SMM, muscle function, and structure in humans. At present, no definitive conclusion can be drawn regarding the potential detrimental or beneficial effects of GLP-1-based therapies on skeletal muscle. Even if most available results are reassuring, further investigations are warranted, especially among individuals at higher risk of sarcopenia as older patients. In any case, the overall benefit/risk ratio of GLP-1-based therapies appears positive in most patients living with type 2 diabetes and/or clinical obesity.</p>","PeriodicalId":12232,"journal":{"name":"Expert Opinion on Drug Safety","volume":" ","pages":"2041-2052"},"PeriodicalIF":3.0,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147480164","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}